Consortium
15 beneficiaries and 5 partner organisations
3rd – 7th May 2023, Crete, Greece
15 beneficiaries and 5 partner organisations
our activities and social networks
28th -30th September 2022
Consejo Superior de Investigaciones Cientificas, Universitad Autonoma de Madrid
3rd – 7th May 2023, Crete, Greece
Universita’ Degli Studi Di Milano-Bicocca, Dept. of Biotechnology and Bioscience, Italy
University Medical Center Groningen, ERIBA/ Ageing biology and Stem Cells, Netherland
Centre Europeen De Recherche En Biologie Et Medicine, Dept. Cancer Biology, France.
KING’S COLLEGE LONDON, Molecular Hematology, United Kingdom
Flowmetric Europe S.p.A, Italy
Università Degli Studi Di Roma La Sapienza, Dept. Biology and Biotechnology “C. Darwin”, Italy
University of Veterinary Medicine, Vienna, Institute of Medical Biochemistry, Austria
Max Planck Institute, Dept. of Cellular and Molecular Immunology, Germany
INSERM, Centre de Recherche en Cancérologie de Marseille, France
Agencia Estatal Consejo Superior De Investigaciones Cientificas, Dept. of Cell Proliferation and Development, Spain.
Institut Curie, Genotoxic Stress and Cancer Unit, France
TEL AVIV UNIVERSITY (Schneider Children’s Medical Centre), Pediatric Hematological Oncology, Israel
Fondazione M. Tettamanti Menotti De Marchi, M. Tettamanti Research Center, Italy
DIAGENODE, Belgium
Foundation of Biomedical Research, Academy of Athens, Basic Research Center, Greece
Beneficiary: UMCG, CERBM-GIE, FM EU S.P.A. and MPG
Beneficiary: UNIMIB, CERBM-GIE, SAPIENZA, Vetmeduni Vienna and CSIC
Beneficiary: INSTITUT CURIE, TAU, FT, DIAGENODE and BRFAA
Beneficiary: UNIMIB, UMCG, CERBM-GIE, KCL, FM EU S.P.A., SAPIENZA, Vetmeduni Vienna, MPG, INSERM, CSIC, INSTITUT CURIE, TAU, FT, DIAGENODE and BRFAA
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813091